Abstract:High affinity binding of peptides to Src homology 2 (SH2) domains, often requires the presence of phosphotyrosyl (pTyr) or pTyr-mimicking moieties in the N-terminal position of the binding ligand. Several reports have shown that Nα-acylation of the critical pTyr residue can result in increased SH2 domain binding potency. For Grb2 SH2 domains which recognize pTyr-Xxx-Asn-NH2 motifs, significant potency enhancement can be incurred by Nα-(3-amino)Z derivatization of tripeptides such as pTyr-Ile-Asn-NH2. Using ligands based on the high affinity pY-Ac6c-Asn-(naphthylpropylamide) motif, (where Ac6c=1-aminocyclohexanecarboxylic acid), additional reports have shown moderate potentiating effects of Nα-oxalyl derivatization. The current study examined variations of the Nα-oxalyl theme in the context of a Xxx-Ac6c-Asn-(naphthylpropylamide) platform, where Xxx=the hydrolytically stable pTyr mimetics phosphonomethyl phenylalanine (Pmp) or carboxymethyl phenylalanine (Cmf). The effects of Nα-(3-amino)Z derivatization were also investigated for this platform, to ascertain whether the large binding enhancement reported for tripeptides such as pTyr-Ile-Asn-NH2 could be observed. In ELISA-based extracellular Grb2 SH2 domain binding assays, it was found for the Pmp-based series, that extending the oxalyl carboxyl out by one methylene unit or replacing carboxyl functionality with a tetrazole isostere, resulted in binding potency greater than the parent Nα-acetyl-containing compound, with enhancement approximating that observed for the Nα-oxalyl derivative. When Cmf was used as the pTyr mimetic, only modest differences in IC50 values were observed for the series. Examination of the Nα-(3-amino)Z derivatized Pmp-Ac6c-Asn-(naphthylpropylamide), showed that binding affinity was reduced relative to the parent Nα-acetyl analogue, in contrast to the reported significant enhancement of affinity observed with other peptide ligands. Treatment of MDA-453 tumor cells, which are mitogenically driven through erbB-2 tyrosine kinase-dependent pathways, with Pmp-containing inhibitors resulted in growth inhibition, with the Nα-oxalyl and Nα-malonyl-containing compounds exhibiting IC50 values (4.3 and 4.6 μM, respectively) approximately five-fold lower than the parent Nα-acetyl-containing compound. Tetrazole and Nα-(3-amino)Z-containing inhibitors were from two- to four-fold less potent than these latter analogues in the growth inhibition assays.

Structural Requirements for Tyr in the Consensus Sequence Y-E-N of a Novel Nonphosphorylated Inhibitor to the Grb2-SH2 Domain.

Functional Preference of the Constituent Amino Acid Residues in a Phage-Library-based Nonphosphorylated Inhibitor of the Grb2-SH2 Domain.

Potentiating Effect of Distant Sites in Non-Phosphorylated Cyclic Peptide Antagonists of the Grb2-SH2 Domain

Significant Compensatory Role of Position Y-2 Conferring High Affinity to Non-Phosphorylated Inhibitors of Grb2-SH2 Domain

Global Optimization of Conformational Constraint on Non-Phosphorylated Cyclic Peptide Antagonists of the Grb2-SH2 Domain

Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity.

Structure-based design of thioether-bridged cyclic phosphopeptides binding to Grb2-SH2 domain.

Discovery of A Novel Nonphosphorylated Pentapeptide Motif Displaying High Affinity for Grb2-Sh2 Domain by the Utilization of 3 '-Substituted Tyrosine Derivatives

Utilization Of 3 '-Carboxy-Containing Tyrosine Derivatives As A New Class Of Phosphotyrosyl Mimetics In The Preparation Of Novel Non-Phosphorylated Cyclic Peptide Inhibitors Of The Grb2-Sh2 Domain

N-Terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding

Synthesis of a phosphotyrosyl analogue having χ1, χ2 and φ angles constrained to values observed for an SH2 domain-bound phosphotyrosyl residue

Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity.

Synthesis and Utilization of Chiral α-Methylated α-Amino Acids with a Carboxyalkyl Side Chain in the Design of Novel Grb2-SH2 Peptide Inhibitors Free of Phosphotyrosine

Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition.

Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.

Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.

Tyrosine 308 is Necessary for Ligand-directed Gs Protein-biased Signaling of Β2-Adrenoceptor

Tyr306 Near the C‐terminus of Protein Phosphatase‐1 Affects Enzyme Stability and Inhibitor Binding

Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains

Tyr178 of beta3 is critical for alphaIIb maturation and macromolecular ligand binding to alphaIIbbeta3.

Tyr178 of β3 is critical for αIIb maturation and macromolecular ligand binding to αIIbβ3